6562. Verutal-T tablets.    (Inj. No. 335.    S. No. 39-980 P.)
PETITION FILED: 11-5-59, N. Dist. N.Y., against Rand Pharmaceutical Co., 
Inc., Rensselaer, N.Y., to show cause why it should not be punished for crim- 
inal contempt for violation of the permanent injunction which had been entered 
against the Delmar Pharmacal Corp., on 7-22-58 (see preceding notice of 
judgment No. 6546).
LABEL IN PART : "Verutal-T * * * Bach tablet contains: Veratrum Viride 100 
mg.   Rutin 10 mg.   Reserpine .075 mg.   Mannitol Hexanitrate y? gr."
RESULTS OP INVESTIGATION: Analysis showed that the article contained 22 
percent of the labeled amount of mannitol hexanitrate and 66 percent of the 
declared amount of rutin.
CHARGE: The petition alleged that the Rand Pharmaceutical Co., Inc., on 10- 
11-58, caused to be introduced and delivered for introduction into interstate 
commerce at Rensselaer, N.Y., for delivery to South San Francisco, Calif., a 
number of bottles of "Verutal-T" which were adulterated within the meaning 
of 501(c) in that the strength of the drug differed from that which it pur- 
ported and was represented to possess.
It was alleged further that the Rand Pharmaceutical Co., Inc., had been 
and was affiliated with the Delmar Pharmacal Oorp. in the distribution of 
drugs in interstate commerce, and that Rand Pharmaceutical Co., Inc., had 
violated the injunction by causing the adulterated drug to be introduced and 
delivered for introduction into interstate commerce while the Delmar Pharma- 
cal Corp. continued to operate its plant without complying with the following 
requirements of the injunction:
(a) that sufficient qualified and experienced personnel be employed to 
properly operate the plant;
(b) that incoming raw materials be analyzed;
(c) that all finished products be analyzed; and
(d) that a control system be installed which a representative of the 
U.S. Food and Drug Administration had determined to be adequate 
and which embodied all of the safeguards listed in the injunction 
as necessary to good pharmaceutical manufacturing practice.
?See also No. 6546.
DISPOSITION : On 11-5-59, the order to show cause was issued. Thereafter, the 
defendant pled guilty to the charge of violating the injunction and, on 3-21- 
60, the court fined the defendant $1,000.